A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study
Identifieur interne : 000A30 ( Istex/Corpus ); précédent : 000A29; suivant : 000A31A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study
Auteurs : Thomas Felix Lscher ; Michael Pieper ; Michael Tendera ; Mathy Vrolix ; Wolfgang Rutsch ; Frank Van Den Branden ; Robert Gil ; Karl-Otto Bischoff ; Michael Haude ; Dieter Fischer ; Thomas Meinertz ; Thomas MnzelSource :
- European Heart Journal [ 0195-668X ] ; 2009-07.
Abstract
Aims Endothelial dysfunction and plaque formation are features of atherosclerosis. Inhibition of L-type calcium channels or HMG-CoA pathway improves endothelial function and reduces plaque size. Thus, we investigated in stable coronary artery disease (CAD) the effects of a calcium antagonist on coronary endothelial function and plaque size. Methods and results In 454 patients undergoing PCI, acetylcholine (106 to 104 M) was infused in a coronary segment without significant CAD. Changes in coronary diameter were measured and an intravascular ultrasound examination (IVUS) was performed. On top of statin therapy, patients were randomized in a double-blind fashion to placebo or nifedipine GITS 3060 mg/day and followed for 1824 months. Blood pressure was lower on nifedipine than on placebo by 5.8/2.1 mmHg (P < 0.001) as was total and LDL cholesterol (4.8 mg/dL; P = 0.495), while HDL was higher (3.6 mg/dL; P = 0.026). In the most constricting segment, nifedipine reduced vasoconstriction to acetylcholine (14.0% vs. placebo 7.7%; P < 0.0088). The percentage change in plaque volume with nifedipine and placebo, respectively, was 1.0 and 1.9%, ns. Conclusion The ENCORE II trial demonstrates in a multi-centre setting that calcium channel blockade with nifedipine for up to 2 years improves coronary endothelial function on top of statin treatment, but did not show an effect of nifedipine on plaque volume.
Url:
DOI: 10.1093/eurheartj/ehp151
Links to Exploration step
ISTEX:8D439B1DF11795B3238BE2229758042B7A92720ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study</title><author><name sortKey="Lscher, Thomas Felix" sort="Lscher, Thomas Felix" uniqKey="Lscher T" first="Thomas Felix" last="Lscher">Thomas Felix Lscher</name><affiliation><mods:affiliation>Department of Cardiology, Universittsspital, Ramistrassee 100, CH-8091 Zrich, Switzerland</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: cardiotfl@gmx.ch</mods:affiliation></affiliation></author><author><name sortKey="Pieper, Michael" sort="Pieper, Michael" uniqKey="Pieper M" first="Michael" last="Pieper">Michael Pieper</name><affiliation><mods:affiliation>Herz- und Neuro-Zentrum Bodensee, Kreuzlingen, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Tendera, Michael" sort="Tendera, Michael" uniqKey="Tendera M" first="Michael" last="Tendera">Michael Tendera</name><affiliation><mods:affiliation>Silesian School of Medicine, Katowice, Poland</mods:affiliation></affiliation></author><author><name sortKey="Vrolix, Mathy" sort="Vrolix, Mathy" uniqKey="Vrolix M" first="Mathy" last="Vrolix">Mathy Vrolix</name><affiliation><mods:affiliation>Algemeen Ziekenhuis St Jan, Genk, Belgium</mods:affiliation></affiliation></author><author><name sortKey="Rutsch, Wolfgang" sort="Rutsch, Wolfgang" uniqKey="Rutsch W" first="Wolfgang" last="Rutsch">Wolfgang Rutsch</name><affiliation><mods:affiliation>Klinikum Charit der Humboldt Universitt, Berlin, Germany</mods:affiliation></affiliation></author><author><name sortKey="Van Den Branden, Frank" sort="Van Den Branden, Frank" uniqKey="Van Den Branden F" first="Frank" last="Van Den Branden">Frank Van Den Branden</name><affiliation><mods:affiliation>A. Z. Middelheim, Antwerp, Belgium</mods:affiliation></affiliation></author><author><name sortKey="Gil, Robert" sort="Gil, Robert" uniqKey="Gil R" first="Robert" last="Gil">Robert Gil</name><affiliation><mods:affiliation>Klinika Kardiologii Inwazyjnej, Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Bischoff, Karl Otto" sort="Bischoff, Karl Otto" uniqKey="Bischoff K" first="Karl-Otto" last="Bischoff">Karl-Otto Bischoff</name><affiliation><mods:affiliation>Kreiskrankenhaus Waldbrl, Waldbrl, Germany</mods:affiliation></affiliation></author><author><name sortKey="Haude, Michael" sort="Haude, Michael" uniqKey="Haude M" first="Michael" last="Haude">Michael Haude</name><affiliation><mods:affiliation>Universittsklinikum Essen, Essen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Fischer, Dieter" sort="Fischer, Dieter" uniqKey="Fischer D" first="Dieter" last="Fischer">Dieter Fischer</name><affiliation><mods:affiliation>Medical School, Hanover, Germany</mods:affiliation></affiliation></author><author><name sortKey="Meinertz, Thomas" sort="Meinertz, Thomas" uniqKey="Meinertz T" first="Thomas" last="Meinertz">Thomas Meinertz</name><affiliation><mods:affiliation>Universittsklinikum Eppendorf, Hamburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Mnzel, Thomas" sort="Mnzel, Thomas" uniqKey="Mnzel T" first="Thomas" last="Mnzel">Thomas Mnzel</name><affiliation><mods:affiliation>Universittsklinikum Eppendorf, Hamburg, Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8D439B1DF11795B3238BE2229758042B7A92720E</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1093/eurheartj/ehp151</idno><idno type="url">https://api.istex.fr/document/8D439B1DF11795B3238BE2229758042B7A92720E/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000A30</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study</title><author><name sortKey="Lscher, Thomas Felix" sort="Lscher, Thomas Felix" uniqKey="Lscher T" first="Thomas Felix" last="Lscher">Thomas Felix Lscher</name><affiliation><mods:affiliation>Department of Cardiology, Universittsspital, Ramistrassee 100, CH-8091 Zrich, Switzerland</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: cardiotfl@gmx.ch</mods:affiliation></affiliation></author><author><name sortKey="Pieper, Michael" sort="Pieper, Michael" uniqKey="Pieper M" first="Michael" last="Pieper">Michael Pieper</name><affiliation><mods:affiliation>Herz- und Neuro-Zentrum Bodensee, Kreuzlingen, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="Tendera, Michael" sort="Tendera, Michael" uniqKey="Tendera M" first="Michael" last="Tendera">Michael Tendera</name><affiliation><mods:affiliation>Silesian School of Medicine, Katowice, Poland</mods:affiliation></affiliation></author><author><name sortKey="Vrolix, Mathy" sort="Vrolix, Mathy" uniqKey="Vrolix M" first="Mathy" last="Vrolix">Mathy Vrolix</name><affiliation><mods:affiliation>Algemeen Ziekenhuis St Jan, Genk, Belgium</mods:affiliation></affiliation></author><author><name sortKey="Rutsch, Wolfgang" sort="Rutsch, Wolfgang" uniqKey="Rutsch W" first="Wolfgang" last="Rutsch">Wolfgang Rutsch</name><affiliation><mods:affiliation>Klinikum Charit der Humboldt Universitt, Berlin, Germany</mods:affiliation></affiliation></author><author><name sortKey="Van Den Branden, Frank" sort="Van Den Branden, Frank" uniqKey="Van Den Branden F" first="Frank" last="Van Den Branden">Frank Van Den Branden</name><affiliation><mods:affiliation>A. Z. Middelheim, Antwerp, Belgium</mods:affiliation></affiliation></author><author><name sortKey="Gil, Robert" sort="Gil, Robert" uniqKey="Gil R" first="Robert" last="Gil">Robert Gil</name><affiliation><mods:affiliation>Klinika Kardiologii Inwazyjnej, Warsaw, Poland</mods:affiliation></affiliation></author><author><name sortKey="Bischoff, Karl Otto" sort="Bischoff, Karl Otto" uniqKey="Bischoff K" first="Karl-Otto" last="Bischoff">Karl-Otto Bischoff</name><affiliation><mods:affiliation>Kreiskrankenhaus Waldbrl, Waldbrl, Germany</mods:affiliation></affiliation></author><author><name sortKey="Haude, Michael" sort="Haude, Michael" uniqKey="Haude M" first="Michael" last="Haude">Michael Haude</name><affiliation><mods:affiliation>Universittsklinikum Essen, Essen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Fischer, Dieter" sort="Fischer, Dieter" uniqKey="Fischer D" first="Dieter" last="Fischer">Dieter Fischer</name><affiliation><mods:affiliation>Medical School, Hanover, Germany</mods:affiliation></affiliation></author><author><name sortKey="Meinertz, Thomas" sort="Meinertz, Thomas" uniqKey="Meinertz T" first="Thomas" last="Meinertz">Thomas Meinertz</name><affiliation><mods:affiliation>Universittsklinikum Eppendorf, Hamburg, Germany</mods:affiliation></affiliation></author><author><name sortKey="Mnzel, Thomas" sort="Mnzel, Thomas" uniqKey="Mnzel T" first="Thomas" last="Mnzel">Thomas Mnzel</name><affiliation><mods:affiliation>Universittsklinikum Eppendorf, Hamburg, Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">European Heart Journal</title><idno type="ISSN">0195-668X</idno><idno type="eISSN">1522-9645</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2009-07">2009-07</date><biblScope unit="volume">30</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="1590">1590</biblScope><biblScope unit="page" to="1597">1597</biblScope></imprint><idno type="ISSN">0195-668X</idno></series><idno type="istex">8D439B1DF11795B3238BE2229758042B7A92720E</idno><idno type="DOI">10.1093/eurheartj/ehp151</idno><idno type="ArticleID">ehp151</idno><idno type="related-article-ID">RA1</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0195-668X</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Aims Endothelial dysfunction and plaque formation are features of atherosclerosis. Inhibition of L-type calcium channels or HMG-CoA pathway improves endothelial function and reduces plaque size. Thus, we investigated in stable coronary artery disease (CAD) the effects of a calcium antagonist on coronary endothelial function and plaque size. Methods and results In 454 patients undergoing PCI, acetylcholine (106 to 104 M) was infused in a coronary segment without significant CAD. Changes in coronary diameter were measured and an intravascular ultrasound examination (IVUS) was performed. On top of statin therapy, patients were randomized in a double-blind fashion to placebo or nifedipine GITS 3060 mg/day and followed for 1824 months. Blood pressure was lower on nifedipine than on placebo by 5.8/2.1 mmHg (P < 0.001) as was total and LDL cholesterol (4.8 mg/dL; P = 0.495), while HDL was higher (3.6 mg/dL; P = 0.026). In the most constricting segment, nifedipine reduced vasoconstriction to acetylcholine (14.0% vs. placebo 7.7%; P < 0.0088). The percentage change in plaque volume with nifedipine and placebo, respectively, was 1.0 and 1.9%, ns. Conclusion The ENCORE II trial demonstrates in a multi-centre setting that calcium channel blockade with nifedipine for up to 2 years improves coronary endothelial function on top of statin treatment, but did not show an effect of nifedipine on plaque volume.</div></front></TEI><istex><corpusName>oup</corpusName><author><json:item><name>Thomas Felix Lscher</name><affiliations><json:string>Department of Cardiology, Universittsspital, Ramistrassee 100, CH-8091 Zrich, Switzerland</json:string><json:string>E-mail: cardiotfl@gmx.ch</json:string></affiliations></json:item><json:item><name>Michael Pieper</name><affiliations><json:string>Herz- und Neuro-Zentrum Bodensee, Kreuzlingen, Switzerland</json:string></affiliations></json:item><json:item><name>Michael Tendera</name><affiliations><json:string>Silesian School of Medicine, Katowice, Poland</json:string></affiliations></json:item><json:item><name>Mathy Vrolix</name><affiliations><json:string>Algemeen Ziekenhuis St Jan, Genk, Belgium</json:string></affiliations></json:item><json:item><name>Wolfgang Rutsch</name><affiliations><json:string>Klinikum Charit der Humboldt Universitt, Berlin, Germany</json:string></affiliations></json:item><json:item><name>Frank van den Branden</name><affiliations><json:string>A. Z. Middelheim, Antwerp, Belgium</json:string></affiliations></json:item><json:item><name>Robert Gil</name><affiliations><json:string>Klinika Kardiologii Inwazyjnej, Warsaw, Poland</json:string></affiliations></json:item><json:item><name>Karl-Otto Bischoff</name><affiliations><json:string>Kreiskrankenhaus Waldbrl, Waldbrl, Germany</json:string></affiliations></json:item><json:item><name>Michael Haude</name><affiliations><json:string>Universittsklinikum Essen, Essen, Germany</json:string></affiliations></json:item><json:item><name>Dieter Fischer</name><affiliations><json:string>Medical School, Hanover, Germany</json:string></affiliations></json:item><json:item><name>Thomas Meinertz</name><affiliations><json:string>Universittsklinikum Eppendorf, Hamburg, Germany</json:string></affiliations></json:item><json:item><name>Thomas Mnzel</name><affiliations><json:string>Universittsklinikum Eppendorf, Hamburg, Germany</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Acetylcholine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Angiography</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Endothelium</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>IVUS</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Plaque</value></json:item></subject><articleId><json:string>ehp151</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>Aims Endothelial dysfunction and plaque formation are features of atherosclerosis. Inhibition of L-type calcium channels or HMG-CoA pathway improves endothelial function and reduces plaque size. Thus, we investigated in stable coronary artery disease (CAD) the effects of a calcium antagonist on coronary endothelial function and plaque size. Methods and results In 454 patients undergoing PCI, acetylcholine (106 to 104 M) was infused in a coronary segment without significant CAD. Changes in coronary diameter were measured and an intravascular ultrasound examination (IVUS) was performed. On top of statin therapy, patients were randomized in a double-blind fashion to placebo or nifedipine GITS 3060 mg/day and followed for 1824 months. Blood pressure was lower on nifedipine than on placebo by 5.8/2.1 mmHg (P > 0.001) as was total and LDL cholesterol (4.8 mg/dL; P = 0.495), while HDL was higher (3.6 mg/dL; P = 0.026). In the most constricting segment, nifedipine reduced vasoconstriction to acetylcholine (14.0% vs. placebo 7.7%; P > 0.0088). The percentage change in plaque volume with nifedipine and placebo, respectively, was 1.0 and 1.9%, ns. Conclusion The ENCORE II trial demonstrates in a multi-centre setting that calcium channel blockade with nifedipine for up to 2 years improves coronary endothelial function on top of statin treatment, but did not show an effect of nifedipine on plaque volume.</abstract><qualityIndicators><score>8.592</score><pdfVersion>1.5</pdfVersion><pdfPageSize>595.276 x 793.701 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1414</abstractCharCount><pdfWordCount>5164</pdfWordCount><pdfCharCount>35735</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>216</abstractWordCount></qualityIndicators><title>A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study</title><genre><json:string>research-article</json:string></genre><host><volume>30</volume><publisherId><json:string>eurheartj</json:string></publisherId><pages><last>1597</last><first>1590</first></pages><issn><json:string>0195-668X</json:string></issn><issue>13</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1522-9645</json:string></eissn><title>European Heart Journal</title></host><categories><wos><json:string>CARDIAC & CARDIOVASCULAR SYSTEMS</json:string></wos></categories><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1093/eurheartj/ehp151</json:string></doi><id>8D439B1DF11795B3238BE2229758042B7A92720E</id><score>0.26681775</score><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/8D439B1DF11795B3238BE2229758042B7A92720E/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/8D439B1DF11795B3238BE2229758042B7A92720E/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/8D439B1DF11795B3238BE2229758042B7A92720E/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Oxford University Press</publisher><availability><p>Published on behalf of the European Society of Cardiology. All rights reserved. The Author 2009. For permissions please email: journals.permissionsoxfordjournals.org</p></availability><date>2009-05-27</date></publicationStmt><notesStmt><note>This manuscript was assessed and accepted for publication by the previous Editorial Office based in Leuven.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study</title><author xml:id="author-1"><persName><forename type="first">Thomas Felix</forename><surname>Lscher</surname></persName><email>cardiotfl@gmx.ch</email><affiliation>Department of Cardiology, Universittsspital, Ramistrassee 100, CH-8091 Zrich, Switzerland</affiliation></author><author xml:id="author-2"><persName><forename type="first">Michael</forename><surname>Pieper</surname></persName><affiliation>Herz- und Neuro-Zentrum Bodensee, Kreuzlingen, Switzerland</affiliation></author><author xml:id="author-3"><persName><forename type="first">Michael</forename><surname>Tendera</surname></persName><affiliation>Silesian School of Medicine, Katowice, Poland</affiliation></author><author xml:id="author-4"><persName><forename type="first">Mathy</forename><surname>Vrolix</surname></persName><affiliation>Algemeen Ziekenhuis St Jan, Genk, Belgium</affiliation></author><author xml:id="author-5"><persName><forename type="first">Wolfgang</forename><surname>Rutsch</surname></persName><affiliation>Klinikum Charit der Humboldt Universitt, Berlin, Germany</affiliation></author><author xml:id="author-6"><persName><forename type="first">Frank</forename><surname>van den Branden</surname></persName><affiliation>A. Z. Middelheim, Antwerp, Belgium</affiliation></author><author xml:id="author-7"><persName><forename type="first">Robert</forename><surname>Gil</surname></persName><affiliation>Klinika Kardiologii Inwazyjnej, Warsaw, Poland</affiliation></author><author xml:id="author-8"><persName><forename type="first">Karl-Otto</forename><surname>Bischoff</surname></persName><affiliation>Kreiskrankenhaus Waldbrl, Waldbrl, Germany</affiliation></author><author xml:id="author-9"><persName><forename type="first">Michael</forename><surname>Haude</surname></persName><affiliation>Universittsklinikum Essen, Essen, Germany</affiliation></author><author xml:id="author-10"><persName><forename type="first">Dieter</forename><surname>Fischer</surname></persName><affiliation>Medical School, Hanover, Germany</affiliation></author><author xml:id="author-11"><persName><forename type="first">Thomas</forename><surname>Meinertz</surname></persName><affiliation>Universittsklinikum Eppendorf, Hamburg, Germany</affiliation></author><author xml:id="author-12"><persName><forename type="first">Thomas</forename><surname>Mnzel</surname></persName><affiliation>Universittsklinikum Eppendorf, Hamburg, Germany</affiliation></author></analytic><monogr><title level="j">European Heart Journal</title><idno type="pISSN">0195-668X</idno><idno type="eISSN">1522-9645</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2009-07"></date><biblScope unit="volume">30</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="1590">1590</biblScope><biblScope unit="page" to="1597">1597</biblScope></imprint></monogr><idno type="istex">8D439B1DF11795B3238BE2229758042B7A92720E</idno><idno type="DOI">10.1093/eurheartj/ehp151</idno><idno type="ArticleID">ehp151</idno><idno type="related-article-ID">RA1</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009-05-27</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Aims Endothelial dysfunction and plaque formation are features of atherosclerosis. Inhibition of L-type calcium channels or HMG-CoA pathway improves endothelial function and reduces plaque size. Thus, we investigated in stable coronary artery disease (CAD) the effects of a calcium antagonist on coronary endothelial function and plaque size. Methods and results In 454 patients undergoing PCI, acetylcholine (106 to 104 M) was infused in a coronary segment without significant CAD. Changes in coronary diameter were measured and an intravascular ultrasound examination (IVUS) was performed. On top of statin therapy, patients were randomized in a double-blind fashion to placebo or nifedipine GITS 3060 mg/day and followed for 1824 months. Blood pressure was lower on nifedipine than on placebo by 5.8/2.1 mmHg (P < 0.001) as was total and LDL cholesterol (4.8 mg/dL; P = 0.495), while HDL was higher (3.6 mg/dL; P = 0.026). In the most constricting segment, nifedipine reduced vasoconstriction to acetylcholine (14.0% vs. placebo 7.7%; P < 0.0088). The percentage change in plaque volume with nifedipine and placebo, respectively, was 1.0 and 1.9%, ns. Conclusion The ENCORE II trial demonstrates in a multi-centre setting that calcium channel blockade with nifedipine for up to 2 years improves coronary endothelial function on top of statin treatment, but did not show an effect of nifedipine on plaque volume.</p></abstract><textClass><keywords scheme="keyword"><list><head>keywords</head><item><term>Acetylcholine</term></item><item><term>Angiography</term></item><item><term>Endothelium</term></item><item><term>IVUS</term></item><item><term>Plaque</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-05-27">Created</change><change when="2009-07">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/8D439B1DF11795B3238BE2229758042B7A92720E/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article"><front><journal-meta><journal-id journal-id-type="hwp">ehj</journal-id><journal-id journal-id-type="publisher-id">eurheartj</journal-id><journal-title>European Heart Journal</journal-title><issn pub-type="ppub">0195-668X</issn><issn pub-type="epub">1522-9645</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1093/eurheartj/ehp151</article-id><article-id pub-id-type="publisher-id">ehp151</article-id><article-categories><subj-group subj-group-type="heading"><subject>CLINICAL RESEARCH</subject><subj-group><subject>Coronary heart disease</subject></subj-group></subj-group><series-title>editor's choice</series-title></article-categories><title-group><article-title>A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study<xref ref-type="fn" rid="FN1">†</xref></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lüscher</surname><given-names>Thomas Felix</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Pieper</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tendera</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Vrolix</surname><given-names>Mathy</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Rutsch</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>van den Branden</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Gil</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Bischoff</surname><given-names>Karl-Otto</given-names></name><xref ref-type="aff" rid="af8">8</xref></contrib><contrib contrib-type="author"><name><surname>Haude</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="af9">9</xref></contrib><contrib contrib-type="author"><name><surname>Fischer</surname><given-names>Dieter</given-names></name><xref ref-type="aff" rid="af10">10</xref></contrib><contrib contrib-type="author"><name><surname>Meinertz</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="af11">11</xref></contrib><contrib contrib-type="author"><name><surname>Münzel</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="af11">11</xref></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>Department of Cardiology</addr-line>, <institution>Universitätsspital</institution>, <addr-line>Ramistrassee 100, CH-8091 Zürich</addr-line>, <country>Switzerland</country></aff><aff id="af2"><label>2</label><institution>Herz- und Neuro-Zentrum Bodensee</institution>, <addr-line>Kreuzlingen</addr-line>, <country>Switzerland</country></aff><aff id="af3"><label>3</label><institution>Silesian School of Medicine</institution>, <addr-line>Katowice</addr-line>, <country>Poland</country></aff><aff id="af4"><label>4</label><institution>Algemeen Ziekenhuis St Jan</institution>, <addr-line>Genk</addr-line>, <country>Belgium</country></aff><aff id="af5"><label>5</label><institution>Klinikum Charité der Humboldt Universität</institution>, <addr-line>Berlin</addr-line>, <country>Germany</country></aff><aff id="af6"><label>6</label><institution>A. Z. Middelheim</institution>, <addr-line>Antwerp</addr-line>, <country>Belgium</country></aff><aff id="af7"><label>7</label><institution>Klinika Kardiologii Inwazyjnej</institution>, <addr-line>Warsaw</addr-line>, <country>Poland</country></aff><aff id="af8"><label>8</label><institution>Kreiskrankenhaus Waldbröl</institution>, <addr-line>Waldbröl</addr-line>, <country>Germany</country></aff><aff id="af9"><label>9</label><institution>Universitätsklinikum Essen</institution>, <addr-line>Essen</addr-line>, <country>Germany</country></aff><aff id="af10"><label>10</label><institution>Medical School</institution>, <addr-line>Hanover</addr-line>, <country>Germany</country></aff><aff id="af11"><label>11</label><institution>Universitätsklinikum Eppendorf</institution>, <addr-line>Hamburg</addr-line>, <country>Germany</country></aff><author-notes><fn id="FN1"><label>†</label><p>This manuscript was assessed and accepted for publication by the previous Editorial Office based in Leuven.</p></fn><corresp id="cor1"><label>*</label>Corresponding author. Tel: <phone>+41 1 255 21 21</phone>, Fax: <fax>+41 1 255 42 51</fax>, Email: <email>cardiotfl@gmx.ch</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>27</day><month>5</month><year>2009</year></pub-date><volume>30</volume><issue>13</issue><fpage>1590</fpage><lpage>1597</lpage><history><date date-type="received"><day>17</day><month>7</month><year>2007</year></date><date date-type="rev-recd"><day>16</day><month>3</month><year>2009</year></date><date date-type="accepted"><day>17</day><month>3</month><year>2009</year></date></history><copyright-statement>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org</copyright-statement><copyright-year>2009</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/"><p>The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org</p></license><related-article related-article-type="in-this-issue" vol="30" page="1556" id="RA1"><bold>See page 1556 for the editorial comment on this article (doi:10.1093/eurheartj/ehp238)</bold></related-article><abstract><sec><title>Aims</title><p>Endothelial dysfunction and plaque formation are features of atherosclerosis. Inhibition of L-type calcium channels or HMG-CoA pathway improves endothelial function and reduces plaque size. Thus, we investigated in stable coronary artery disease (CAD) the effects of a calcium antagonist on coronary endothelial function and plaque size.</p></sec><sec><title>Methods and results</title><p>In 454 patients undergoing PCI, acetylcholine (10<sup>−6</sup> to 10<sup>−4</sup> M) was infused in a coronary segment without significant CAD. Changes in coronary diameter were measured and an intravascular ultrasound examination (IVUS) was performed. On top of statin therapy, patients were randomized in a double-blind fashion to placebo or nifedipine GITS 30–60 mg/day and followed for 18–24 months.</p><p>Blood pressure was lower on nifedipine than on placebo by 5.8/2.1 mmHg (<italic>P</italic> < 0.001) as was total and LDL cholesterol (4.8 mg/dL; <italic>P</italic> = 0.495), while HDL was higher (3.6 mg/dL; <italic>P</italic> = 0.026). In the most constricting segment, nifedipine reduced vasoconstriction to acetylcholine (14.0% vs. placebo 7.7%; <italic>P</italic> < 0.0088). The percentage change in plaque volume with nifedipine and placebo, respectively, was 1.0 and 1.9%, ns.</p></sec><sec><title>Conclusion</title><p>The ENCORE II trial demonstrates in a multi-centre setting that calcium channel blockade with nifedipine for up to 2 years improves coronary endothelial function on top of statin treatment, but did not show an effect of nifedipine on plaque volume.</p></sec></abstract><kwd-group><kwd>Acetylcholine</kwd><kwd>Angiography</kwd><kwd>Endothelium</kwd><kwd>IVUS</kwd><kwd>Plaque</kwd></kwd-group></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><partName>editor's choice</partName><title>A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><partName>editor's choice</partName><title>A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study</title></titleInfo><name type="personal"><namePart type="given">Thomas Felix</namePart><namePart type="family">Lscher</namePart><affiliation>Department of Cardiology, Universittsspital, Ramistrassee 100, CH-8091 Zrich, Switzerland</affiliation><affiliation>E-mail: cardiotfl@gmx.ch</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael</namePart><namePart type="family">Pieper</namePart><affiliation>Herz- und Neuro-Zentrum Bodensee, Kreuzlingen, Switzerland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael</namePart><namePart type="family">Tendera</namePart><affiliation>Silesian School of Medicine, Katowice, Poland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mathy</namePart><namePart type="family">Vrolix</namePart><affiliation>Algemeen Ziekenhuis St Jan, Genk, Belgium</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Wolfgang</namePart><namePart type="family">Rutsch</namePart><affiliation>Klinikum Charit der Humboldt Universitt, Berlin, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Frank</namePart><namePart type="family">van den Branden</namePart><affiliation>A. Z. Middelheim, Antwerp, Belgium</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert</namePart><namePart type="family">Gil</namePart><affiliation>Klinika Kardiologii Inwazyjnej, Warsaw, Poland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Karl-Otto</namePart><namePart type="family">Bischoff</namePart><affiliation>Kreiskrankenhaus Waldbrl, Waldbrl, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael</namePart><namePart type="family">Haude</namePart><affiliation>Universittsklinikum Essen, Essen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dieter</namePart><namePart type="family">Fischer</namePart><affiliation>Medical School, Hanover, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Thomas</namePart><namePart type="family">Meinertz</namePart><affiliation>Universittsklinikum Eppendorf, Hamburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Thomas</namePart><namePart type="family">Mnzel</namePart><affiliation>Universittsklinikum Eppendorf, Hamburg, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><originInfo><publisher>Oxford University Press</publisher><dateIssued encoding="w3cdtf">2009-07</dateIssued><dateCreated encoding="w3cdtf">2009-05-27</dateCreated><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Aims Endothelial dysfunction and plaque formation are features of atherosclerosis. Inhibition of L-type calcium channels or HMG-CoA pathway improves endothelial function and reduces plaque size. Thus, we investigated in stable coronary artery disease (CAD) the effects of a calcium antagonist on coronary endothelial function and plaque size. Methods and results In 454 patients undergoing PCI, acetylcholine (106 to 104 M) was infused in a coronary segment without significant CAD. Changes in coronary diameter were measured and an intravascular ultrasound examination (IVUS) was performed. On top of statin therapy, patients were randomized in a double-blind fashion to placebo or nifedipine GITS 3060 mg/day and followed for 1824 months. Blood pressure was lower on nifedipine than on placebo by 5.8/2.1 mmHg (P < 0.001) as was total and LDL cholesterol (4.8 mg/dL; P = 0.495), while HDL was higher (3.6 mg/dL; P = 0.026). In the most constricting segment, nifedipine reduced vasoconstriction to acetylcholine (14.0% vs. placebo 7.7%; P < 0.0088). The percentage change in plaque volume with nifedipine and placebo, respectively, was 1.0 and 1.9%, ns. Conclusion The ENCORE II trial demonstrates in a multi-centre setting that calcium channel blockade with nifedipine for up to 2 years improves coronary endothelial function on top of statin treatment, but did not show an effect of nifedipine on plaque volume.</abstract><note type="footnotes">This manuscript was assessed and accepted for publication by the previous Editorial Office based in Leuven.</note><subject><genre>keywords</genre><topic>Acetylcholine</topic><topic>Angiography</topic><topic>Endothelium</topic><topic>IVUS</topic><topic>Plaque</topic></subject><relatedItem type="host"><titleInfo><title>European Heart Journal</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0195-668X</identifier><identifier type="eISSN">1522-9645</identifier><identifier type="PublisherID">eurheartj</identifier><identifier type="PublisherID-hwp">ehj</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><detail type="issue"><caption>no.</caption><number>13</number></detail><extent unit="pages"><start>1590</start><end>1597</end></extent></part></relatedItem><relatedItem type="reviewOf"><identifier type="in-this-issue"></identifier><part><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>1556</start></extent></part></relatedItem><identifier type="istex">8D439B1DF11795B3238BE2229758042B7A92720E</identifier><identifier type="DOI">10.1093/eurheartj/ehp151</identifier><identifier type="ArticleID">ehp151</identifier><identifier type="related-article-ID">RA1</identifier><accessCondition type="use and reproduction" contentType="copyright">Published on behalf of the European Society of Cardiology. All rights reserved. The Author 2009. For permissions please email: journals.permissionsoxfordjournals.org</accessCondition><recordInfo><recordContentSource>OUP</recordContentSource></recordInfo></mods></metadata><covers><json:item><original>true</original><mimetype>image/tiff</mimetype><extension>tiff</extension><uri>https://api.istex.fr/document/8D439B1DF11795B3238BE2229758042B7A92720E/covers/tiff</uri></json:item><json:item><original>true</original><mimetype>text/html</mimetype><extension>html</extension><uri>https://api.istex.fr/document/8D439B1DF11795B3238BE2229758042B7A92720E/covers/html</uri></json:item></covers><annexes><json:item><original>true</original><mimetype>image/jpeg</mimetype><extension>jpeg</extension><uri>https://api.istex.fr/document/8D439B1DF11795B3238BE2229758042B7A92720E/annexes/jpeg</uri></json:item><json:item><original>true</original><mimetype>image/gif</mimetype><extension>gif</extension><uri>https://api.istex.fr/document/8D439B1DF11795B3238BE2229758042B7A92720E/annexes/gif</uri></json:item><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/8D439B1DF11795B3238BE2229758042B7A92720E/annexes/pdf</uri></json:item></annexes><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/8D439B1DF11795B3238BE2229758042B7A92720E/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">CARDIAC & CARDIOVASCULAR SYSTEMS</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A30 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000A30 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:8D439B1DF11795B3238BE2229758042B7A92720E
|texte= A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study
}}
| This area was generated with Dilib version V0.6.25. |  |